TAVI pioneers discuss the past, present and future of transcatheter therapy
Products
Information
As transcatheter aortic valve implantation (TAVI) moves beyond its 20-year milestone, two pioneers of the treatment—Alain Cribier (University Hospital of Rouen, Rouen, France) and Michael Reardon (Academic Institute Methodist DeBakey Heart & Vascular Center, Houston, USA)—reflect on its wide-reaching impact on the treatment of aortic disease.
